FSM Wealth Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$322K Buy
832
+130
+19% +$48.2K 0.03% 252
2026
Q1
$205K Sell
702
-118
-14% -$38.8K 0.03% 310
2025
Q4
$288K Buy
820
+5
+0.6% +$1.69K 0.04% 248
2025
Q3
$263K Sell
815
-27
-3% -$8.4K 0.04% 257
2025
Q2
$292K Buy
842
+145
+21% +$58.3K 0.05% 223
2025
Q1
$303K Buy
697
+77
+12% +$30.9K 0.07% 155
2024
Q4
$239K Buy
620
+15
+2% +$6.28K 0.06% 163
2024
Q3
$315K Buy
605
+37
+7% +$19.8K 0.08% 125
2024
Q2
$308K Buy
568
+24
+4% +$12.7K 0.1% 113
2024
Q1
$282K Buy
544
+13
+2% +$6.46K 0.1% 127
2023
Q4
$250K Buy
531
+4
+0.8% +$1.85K 0.11% 130
2023
Q3
$229K Sell
527
-7
-1% -$3.17K 0.12% 130
2023
Q2
$232K Sell
534
-104
-16% -$48K 0.12% 141
2023
Q1
$293K Buy
638
+8
+1% +$3.81K 0.17% 118
2022
Q4
$323K Buy
630
+3
+0.5% +$1.52K 0.23% 98
2022
Q3
$285K Buy
+627
New +$300K 0.24% 105

Other funds holding ELV

FSM Wealth Advisors's ELV Position: Q2 2026 in Review

FSM Wealth Advisors increased its Elevance Health (ELV) stake by 19% in Q2 2026, buying an estimated $48.2K and bringing the position to 832 shares worth $322K. The position accounts for 0.03% of the portfolio, ranked #252.

FSM Wealth Advisors first reported a position in ELV in Q3 2022 and has held it in 16 quarters since. The position peaked at $323K in Q4 2022. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • FSM Wealth Advisors held 832 shares of Elevance Health worth $322K as of Q2 2026.
  • FSM Wealth Advisors bought 130 Elevance Health shares in Q2 2026, an estimated $48.2K.
  • Elevance Health made up 0.03% of FSM Wealth Advisors's portfolio in Q2 2026, its #252 holding.
  • FSM Wealth Advisors first reported a position in Elevance Health in Q3 2022 and has held it in 16 quarters since.
  • FSM Wealth Advisors's Elevance Health position peaked at $323K in Q4 2022.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on FSM Wealth Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.